Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE:ZH, SEHK:2390), Roborock (SHSE:688169), UBTech (SEHK:9880), WeRide (NASDAQ:WRD), HyperStrong (SHSE:688411), Insta360 (SHSE:688775), Unisound (SEHK:9678), Gan & Lee Pharmaceuticals (SHSE:603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE:688520), Yuanxin Technology, Insilico Medicine, Medilink Therapeutics, LaNova Medicines, zai, StepFun, among many others.
我们正在追踪 Qiming Venture Partners 的市场扩张
Qiming Venture Partners 的国际扩张与竞争对手的对比情况
Qiming Venture Partners你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Qiming Venture Partners你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Qiming Venture Partners 的业务、市场和增长信号的快速解答。
